932.06
price up icon2.35%   21.37
after-market After Hours: 930.01 -2.05 -0.22%
loading
Lilly Eli Co stock is traded at $932.06, with a volume of 2.24M. It is up +2.35% in the last 24 hours and up +1.21% over the past month. Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.
See More
Previous Close:
$910.69
Open:
$916.04
24h Volume:
2.24M
Relative Volume:
0.75
Market Cap:
$885.83B
Revenue:
$38.92B
Net Income/Loss:
$7.34B
P/E Ratio:
171.99
EPS:
5.4193
Net Cash Flow:
$-3.63B
1W Performance:
+5.06%
1M Performance:
+1.21%
6M Performance:
+22.71%
1Y Performance:
+53.99%
1-Day Range:
Value
$911.18
$932.24
1-Week Range:
Value
$889.57
$932.24
52-Week Range:
Value
$547.61
$972.53

Lilly Eli Co Stock (LLY) Company Profile

Name
Name
Lilly Eli Co
Name
Phone
(317) 276-2000
Name
Address
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Name
Employee
43,000
Name
Twitter
@LillyPad
Name
Next Earnings Date
2024-10-30
Name
Latest SEC Filings
Name
LLY's Discussions on Twitter

Lilly Eli Co Stock (LLY) Upgrades & Downgrades

Date Action Analyst Rating Change
Sep-13-24 Resumed Citigroup Buy
Aug-12-24 Upgrade Deutsche Bank Hold → Buy
Feb-21-24 Downgrade DZ Bank Buy → Hold
Feb-16-24 Reiterated Morgan Stanley Overweight
Dec-21-23 Downgrade Daiwa Securities Buy → Outperform
Nov-09-23 Initiated Deutsche Bank Hold
Oct-20-23 Resumed UBS Buy
Aug-09-23 Upgrade Jefferies Hold → Buy
Jul-26-23 Reiterated Citigroup Buy
Jul-14-23 Initiated HSBC Securities Buy
May-24-23 Reiterated BofA Securities Buy
May-24-23 Reiterated UBS Buy
Mar-13-23 Upgrade Wells Fargo Equal Weight → Overweight
Mar-06-23 Initiated Jefferies Hold
Feb-15-23 Downgrade Societe Generale Hold → Sell
Nov-18-22 Initiated Credit Suisse Outperform
Sep-22-22 Upgrade UBS Neutral → Buy
May-23-22 Initiated SVB Leerink Outperform
Apr-06-22 Resumed Morgan Stanley Overweight
Mar-10-22 Initiated Daiwa Securities Outperform
Jan-21-22 Upgrade DZ Bank Hold → Buy
Jan-03-22 Reiterated Bernstein Mkt Perform
Dec-17-21 Initiated Goldman Neutral
Dec-16-21 Reiterated BMO Capital Markets Outperform
Dec-16-21 Reiterated BofA Securities Buy
Dec-09-21 Resumed Wells Fargo Equal Weight
Nov-19-21 Initiated BMO Capital Markets Outperform
Oct-11-21 Upgrade Berenberg Hold → Buy
Sep-29-21 Upgrade Citigroup Neutral → Buy
Aug-05-21 Upgrade DZ Bank Hold → Buy
Jul-27-21 Resumed Truist Buy
Jun-24-21 Reiterated Cantor Fitzgerald Overweight
Jan-19-21 Upgrade Mizuho Neutral → Buy
Dec-10-20 Upgrade Wolfe Research Peer Perform → Outperform
Nov-10-20 Resumed Bernstein Mkt Perform
Sep-29-20 Initiated Berenberg Hold
Sep-03-20 Upgrade Morgan Stanley Equal-Weight → Overweight
Jun-16-20 Upgrade Guggenheim Neutral → Buy
Apr-21-20 Downgrade UBS Buy → Neutral
Apr-09-20 Downgrade Morgan Stanley Overweight → Equal-Weight
Feb-06-20 Initiated Mizuho Neutral
Dec-18-19 Upgrade Morgan Stanley Equal-Weight → Overweight
Oct-17-19 Resumed BofA/Merrill Buy
May-28-19 Initiated Goldman Buy
Apr-24-19 Upgrade Edward Jones Hold → Buy
Apr-11-19 Downgrade Guggenheim Buy → Neutral
Mar-12-19 Initiated JP Morgan Overweight
Jan-23-19 Initiated UBS Buy
Nov-26-18 Downgrade Citigroup Buy → Neutral
Oct-31-18 Upgrade Credit Suisse Underperform → Neutral
Oct-09-18 Initiated Guggenheim Buy
Oct-01-18 Reiterated SunTrust Buy
Sep-26-18 Resumed JP Morgan Overweight
View All

Lilly Eli Co Stock (LLY) Latest News

pulisher
02:31 AM

Interested in Weight Loss Stocks Besides Novo Nordisk and Eli Lilly? You Might Want To Check Out This New IPO Stock - The Motley Fool

02:31 AM
pulisher
09:52 AM

Eli Lilly and Company (LLY): Among the Most Promising Growth Stocks According to Hedge Funds - Insider Monkey

09:52 AM
pulisher
07:55 AM

FDA to review decison to end of Zepbound shortage (NYSE:LLY) - Seeking Alpha

07:55 AM
pulisher
03:15 AM

The Ultimate Biotech Stock to Buy With $100 Right Now - The Motley Fool

03:15 AM
pulisher
Oct 11, 2024

US FDA to reconsider decision barring compounded versions of Lilly weight loss drug - Reuters.com

Oct 11, 2024
pulisher
Oct 11, 2024

Why Lilly is pouring billions into LEAP - Indianapolis Business Journal

Oct 11, 2024
pulisher
Oct 11, 2024

Eli Lilly Expects Zepbound Approval in Japan by Mid-2025, Eyes Weight-Loss Market - Yahoo Finance

Oct 11, 2024
pulisher
Oct 11, 2024

Eli Lilly obesity drug on track for Japan approval next year: CEO - Nikkei Asia

Oct 11, 2024
pulisher
Oct 11, 2024

Lilly goes all-in on AI with new exec position—Chutes & Ladders - Fierce Biotech

Oct 11, 2024
pulisher
Oct 11, 2024

Eli Lilly (LLY) Stock Price Prediction and Forecast 2025-2030 - 24/7 Wall St.

Oct 11, 2024
pulisher
Oct 11, 2024

Lilly threatens copycat drugmakers after Zepbound shortage - MedWatch

Oct 11, 2024
pulisher
Oct 11, 2024

As Eli Lilly, compounders battle over weight loss drugs, patients are caught in the middle - STAT

Oct 11, 2024
pulisher
Oct 11, 2024

KeyBioscience and Eli Lilly extend partnership for obesity treatments - Pharmaceutical Technology

Oct 11, 2024
pulisher
Oct 11, 2024

Warning: This Skyrocketing Stock Has a Hidden Risk - The Motley Fool

Oct 11, 2024
pulisher
Oct 11, 2024

Nordic Bioscience lands billion-dollar deal with Eli Lilly - MedWatch

Oct 11, 2024
pulisher
Oct 11, 2024

Novo and Lilly contender Zealand Pharma heralds its obesity drug alternative: It's our 'crown jewel' - CNBC

Oct 11, 2024
pulisher
Oct 10, 2024

Eli Lilly Tells Mich. Justices It's 'Wrong Time' For Insulin Case - Law360

Oct 10, 2024
pulisher
Oct 10, 2024

Holcomb appoints Lilly CEO to Purdue board - Inside INdiana Business

Oct 10, 2024
pulisher
Oct 10, 2024

Don't Sleep on Skye Bioscience—This Weight Loss Drug Could Soar - Benzinga

Oct 10, 2024
pulisher
Oct 10, 2024

Michigan AG Seeks State Justices' Aid in Eli Lilly Insulin Probe - Bloomberg Law

Oct 10, 2024
pulisher
Oct 10, 2024

Eli Lilly Issues Cease-And-Desist Letters to Compounders Over Weight-Loss Drug Copies As Shortage Resolves - AOL

Oct 10, 2024
pulisher
Oct 10, 2024

Global Antiemetics Drugs Market to Exhibit Growth at a CAGR of ~6% by 2030 | DelveInsight - GlobeNewswire Inc.

Oct 10, 2024
pulisher
Oct 10, 2024

Eli Lilly Issues Cease-And-Desist Letters to Compounders Over Weight-Loss Drug Copies As Shortage Resolves - Benzinga

Oct 10, 2024
pulisher
Oct 10, 2024

Eli Lilly has an AI chief, telehealth’s DEA troubles, and FDA’s thinking on AI in clinical trials - STAT

Oct 10, 2024
pulisher
Oct 10, 2024

Lilly and insitro team up to develop AI-powered siRNA metabolic drugs - Pharmaceutical Technology

Oct 10, 2024
pulisher
Oct 10, 2024

Lilly threatens legal action against copycat Zepbound providers: report (NYSE:LLY) - Seeking Alpha

Oct 10, 2024
pulisher
Oct 10, 2024

Lilly Fires Warning Shot at Copycat Drug Makers After Shortage - Bloomberg

Oct 10, 2024
pulisher
Oct 10, 2024

Truist highlights ongoing investments in manufacturing as a driver for Eli Lilly shares By Investing.com - Investing.com UK

Oct 10, 2024
pulisher
Oct 10, 2024

Lilly and insitro partner to develop novel drugs for metabolic diseases - World Pharmaceutical Frontiers

Oct 10, 2024
pulisher
Oct 10, 2024

Eli Lilly hires first chief AI officer - MedWatch

Oct 10, 2024
pulisher
Oct 10, 2024

2 No-Brainer Dividend Growth Stocks to Buy Right Now - The Motley Fool

Oct 10, 2024
pulisher
Oct 10, 2024

The Crackdown on Compounded GLP-1 Meds Has Begun - WIRED

Oct 10, 2024
pulisher
Oct 10, 2024

Eli Lilly 2024: The “it” drug - PharmaLive

Oct 10, 2024
pulisher
Oct 09, 2024

Eli Lilly & Co. stock rises Wednesday, still underperforms market - MarketWatch

Oct 09, 2024
pulisher
Oct 09, 2024

On Nobel day for AI in drug discovery, Peninsula biotech, big drugmaker strike AI dealSan Francisco Business Times - The Business Journals

Oct 09, 2024
pulisher
Oct 09, 2024

Lilly, Insitro Ink Unique AI Deal, Eye Novel Treatments for Metabolic Diseases - BioSpace

Oct 09, 2024
pulisher
Oct 09, 2024

Lilly weight-loss drug copycat makers sue FDA for taking drugs off shortage list - Indiana Lawyer

Oct 09, 2024
pulisher
Oct 09, 2024

Prime Medicine lays off workers as it trims pipeline - STAT

Oct 09, 2024
pulisher
Oct 09, 2024

insitro and Lilly Enter Strategic Agreements to Advance Novel Treatments for Metabolic Diseases - Yahoo Finance

Oct 09, 2024
pulisher
Oct 09, 2024

Germany Pharmaceuticals Market Report 2024-2028: Consolidation through Mergers and Acquisitions Catalyzing Growth - GlobeNewswire Inc.

Oct 09, 2024
pulisher
Oct 09, 2024

Here's Why Everybody's Talking About Scholar Rock Right Now - The Motley Fool

Oct 09, 2024
pulisher
Oct 09, 2024

Eli Lilly and Company (LLY): Stock That Will Make You Rich in 5-10 Years - Insider Monkey

Oct 09, 2024
pulisher
Oct 09, 2024

Eli Lilly and Company (LLY): Stock That Will Make You Rich in 5-10 Years - Yahoo Finance

Oct 09, 2024
pulisher
Oct 09, 2024

Lilly’s Sprawling Obesity Clinical Program Underscores Challenges for Biotechs - BioSpace

Oct 09, 2024
pulisher
Oct 08, 2024

Why Eli Lilly Was Such a Healthy Stock Today - The Motley Fool

Oct 08, 2024
pulisher
Oct 08, 2024

Working Together To Advance Health Equity - Essence

Oct 08, 2024
pulisher
Oct 08, 2024

Lilly weight-loss drug copycat makers sue FDA for taking drugs off shortage list - Indianapolis Business Journal

Oct 08, 2024
pulisher
Oct 08, 2024

Stock Quote & Chart - Investors | Eli Lilly and Company

Oct 08, 2024
pulisher
Oct 08, 2024

Qinotto and Lilly Enter Research Collaboration and License Agreement - GlobeNewswire Inc.

Oct 08, 2024
pulisher
Oct 08, 2024

Eli Lilly obesity drug shortage ends fueling lawsuit against FDA - MSN

Oct 08, 2024
pulisher
Oct 08, 2024

Lilly appoints Thomas J. Fuchs as the company’s first chief AI officer - Investors | Eli Lilly and Company

Oct 08, 2024

Lilly Eli Co Stock (LLY) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Lilly Eli Co Stock (LLY) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
LILLY ENDOWMENT INC
10% Owner
Sep 03 '24
Sale
966.69
24,084
23,281,840
96,891,978
LILLY ENDOWMENT INC
10% Owner
Aug 27 '24
Sale
968.46
24,552
23,777,668
96,916,062
drug_manufacturers_general JNJ
$161.46
price up icon 0.59%
$194.19
price down icon 0.08%
drug_manufacturers_general MRK
$109.73
price up icon 0.30%
drug_manufacturers_general NVS
$116.22
price up icon 1.23%
$328.35
price up icon 2.29%
Cap:     |  Volume (24h):